Karyopharm reports third quarter 2019 financial results

Karyopharm reports third quarter 2019 financial results and highlights recent company progress.q3 loss per share $0.67.q3 earnings per share estimate $-0.83 -- refinitiv ibes data.license and other revenue for q3 2019 was $0.3 million, compared to $0.2 million for q3 of 2018.net product revenue for quarter ended september 30, 2019 was $12.8 million.sees 2019 non-gaap operating expenses to be in range of $200 million to $210 million.
KPTI Ratings Summary
KPTI Quant Ranking